ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1565

Association of the gastrointestinal (GI) microbiome and GI symptoms in systemic sclerosis: An international, multi-center, observational study

Zsuzsanna McMahan1, Swapna Joshi2, Jennifer Labus2, Arissa Young2, Andrea Low3, Vanessa Smith4, Susanna Proudman5, Antonia Valenzuela6, Phoebe Hunter7, Kristofer Andréasson8, Ezinne Aja2, Jonathan Jacobs2 and Elizabeth Volkmann9, 1UT Health Houston, Houston, TX, 2UCLA, Los Angeles, 3Singapore General Hospital, SingHealth; Duke-NUS, Singapore, Singapore, 4Ghent University Hospital, Gent, Belgium, 5Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, 6Pontificia Universidad Catolica de Chile, Santiago, Chile, 7Royal Adelaide Hospital, Adelaide, Australia, 8Skåne University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, 9Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA

Meeting: ACR Convergence 2025

Keywords: microbiome, Scleroderma, Scleroderma, Systemic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: GI disease is highly prevalent in systemic sclerosis (SSc) and adversely affects quality of life and survival in SSc. The pathogenesis of GI disease in SSc is poorly understood; however, accumulating evidence suggests that alterations in the GI microbiome occur early in the SSc disease course [1] and are associated with specific SSc phenotypes [2]. No prior studies have investigated whether specific bacterial species associate with GI symptoms. The purpose of this study was to identify bacterial species associated with GI symptom severity in patients with SSc from across the world.

Methods: SSc patients from 7 SSc centers across 5 continents provided a stool sample. Shotgun metagenomic sequencing was performed using the Illumina NovaSeq 6000 to characterize microbial composition at the species level. The UCLA GIT 2.0 was administered at the time of the stool collection to evaluate GI symptom severity. Multivariate Sparse Partial Least Squares Regression (sPLS-R) was used to examine whether there was a species signature associated with GI symptom severity, controlling for body mass index, current proton pump inhibitor use, current supplemental probiotic use, current or prior immunomodulatory therapy, presence of small intestinal bacterial overgrowth, interstitial lung disease and study site.

Results: Of the 274 participants, 83.5% were female, and 13.9% had SIBO. The mean (SD) disease duration was 9.49 (9.29) years. Among 257 bacterial species, the multivariate s-PLS-R identified a linear combination of 8 species associated with total GIT 2.0 score (r=0.38 (95% CI 0.24, 0.50), t(170)=5.29, p < 0.0001) (Figure 1). In terms of specific lower GI symptoms, s-PLS-R identified a linear combination of 15 species associated with constipation score (r=0.45 (95%CI 0.32, 0.56), t(171)=6.60, p < 0.0001) (Figure 2) and a linear combination of 9 species associated with distension score (r=0.37 (95%CI 0.23, 0.49), t(174)=5.18, p < 0.0001) (Figure 3). Six of the 8 species associated with total GIT 2.0 scores overlapped with species associated with either constipation or distension scores.

Conclusion: The results of this cross-sectional, international study demonstrate that the abundance of specific intestinal bacterial species in patients with SSc is associated with the severity of GI disease. These species and/or their metabolic products may serve as markers of GI disease severity in SSc and potentially contribute to SSc-GI pathogenesis. References1. Bellando-Randone S, et al. RMD Open. 2024;10:e004647. 2. Andréasson K, et al. ACR Open Rheumatol. 2022;4:417–25.

Supporting image 1Figure 1. Feature loadings on the species-derived Total GIT 2.0 symptom severity signature from sPLS-R analysis (N&#3f172). Features are ranked from highest (bottom) to lowest (top); species with higher loadings (i.e., weights) contributed the most to the signature score. For each species, positive and negative loadings reflect positive (orange bars) and negative association (blue bars) between that species and Total GIT 2.0 scores.

Supporting image 2Figure 2. Feature loadings on the species-derived constipation severity signature from sPLS-R analysis (N&#3f172). Features are ranked from highest (bottom) to lowest (top); species with higher loadings (i.e., weights) contributed the most to the signature score. For each species, positive and negative loadings reflect positive (orange bars) and negative association (blue bars) between that species and constipation scores.

Supporting image 3Figure 3. Feature loadings on the species-derived distension severity signature from sPLS-R analysis (N&#3f172). Features are ranked from highest (bottom) to lowest (top); species with higher loadings (i.e., weights) contributed the most to the signature score. For each species, positive and negative loadings reflect positive (orange bars) and negative association (blue bars) between that species and distension scores.


Disclosures: Z. McMahan: Aera Therapeutics, 2, Allogene, 2, Boehringer-Ingelheim, 2, guidepoint, 2; S. Joshi: None; J. Labus: None; A. Young: None; A. Low: Boehringer-Ingelheim, 2, 5, 6, 12, Support for attending meetings; DSMB, Janssen, 2, 6, Neuquin Biopharm Pte Ltd, 1, Novartis, 6; V. Smith: Argenx, 2, Boehringer-Ingelheim, 2, 5, 6, GlaxoSmithKlein(GSK), 2, Janssen, 2, 5, 6; S. Proudman: Boehringer-Ingelheim, 5, 6, Janssen, 5, 6, Merck/MSD, 1; A. Valenzuela: None; P. Hunter: None; K. Andréasson: Janssen, 6; E. Aja: None; J. Jacobs: None; E. Volkmann: AbbVie, 2, Boehringer-Ingelheim, 2, 5, 6, 12, Medical writing support provided by Fleishman Hillard, Bristol-Myers Squibb(BMS), 2, GlaxoSmithKleine, 2, 5, Horizon, 5, Kadmon, 5, Prometheus, 5, The National Heart, Lung and Blood Institute, 5.

To cite this abstract in AMA style:

McMahan Z, Joshi S, Labus J, Young A, Low A, Smith V, Proudman S, Valenzuela A, Hunter P, Andréasson K, Aja E, Jacobs J, Volkmann E. Association of the gastrointestinal (GI) microbiome and GI symptoms in systemic sclerosis: An international, multi-center, observational study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/association-of-the-gastrointestinal-gi-microbiome-and-gi-symptoms-in-systemic-sclerosis-an-international-multi-center-observational-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-the-gastrointestinal-gi-microbiome-and-gi-symptoms-in-systemic-sclerosis-an-international-multi-center-observational-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology